Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says

Published on 17 Nov 2024 on Bloomberg · via Yahoo Finance

(Bloomberg) -- Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed...

Read the rest of the article

Start tracking your investments with Statfolio

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on...

Zacks · via Yahoo Finance 9 Jan 2025

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its...

Zacks · via Yahoo Finance 9 Jan 2025

LDOS, Amazon.com, Inc. AMZN, Halozyme Therapeutics, Inc. HALO and BioMarin Pharmaceutical Inc. BM...

Zacks · via Yahoo Finance 7 Jan 2025

Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acqu...

Zacks · via Yahoo Finance 25 Nov 2024

Have a confidential tip for our reporters? Halozyme Therapeutics Inc. withdrew its bid to purchas...

Bloomberg 22 Nov 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announc...

Benzinga · via Yahoo Finance 22 Nov 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announc...

Benzinga · via AOL 22 Nov 2024

Halozyme says the combined company would have an estimated $2 billion in revenue in 2025.

Market Watch 18 Nov 2024

(Bloomberg) -- Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed...

Bloomberg · via Yahoo Finance 17 Nov 2024

On Thursday, Halozyme Therapeutics, Inc. (NASDAQ:HALO) submitted a non-binding proposal to Evotec...

Benzinga · via Yahoo Finance 15 Nov 2024